Document Detail


Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines.
MedLine Citation:
PMID:  20699249     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Several evidences suggest that cancer cells have abnormal cholesterol biosynthetic pathways and prenylation of small guanosine triphosphatase proteins. Tomato lycopene has been suggested to have beneficial effects against certain types of cancer, including that of prostate, although the exact molecular mechanism(s) is unknown. We tested the hypothesis that lycopene may exert its antitumor effects through changes in mevalonate pathway and in Ras activation. Incubation of the Ras-activated prostatic carcinoma LNCaP cells with a 24 h lycopene treatment (2.5-10 μM) dose dependently reduced intracellular total cholesterol by decreasing 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase expression and by inactivating Ras, as evidenced by its translocation from cell membranes to cytosol. Concomitantly, lycopene reduced the Ras-dependent activation of nuclear factor-kappaB (NF-κB). Such a reduction was parallel to an inhibition of reactive oxygen species production and to a decrease in the phosphorylation ofc-jun N-terminal kinase, extracellular signal-regulated kinase 1/2 and p38. These effects were also accompanied by an arrest of cell cycle progression and by apoptosis induction, as evidenced by a decrease in cyclin D1 and phospho-AKT levels and by an increase in p21, p27 and p53 levels and in Bax:Bcl-2 ratio. The addition of mevalonate prevented the growth-inhibitory effects of lycopene as well as its increase in Ras cytoplasmatic accumulation and the subsequent changes in NF-κB. The ability of lycopene in inhibiting HMG-CoA reductase expression and cell growth and in inactivating Ras was also found in prostate PC-3, colon HCT-116 and HT-29 and lung BEN cancer cells. These findings provide a novel mechanistic insight into the growth-inhibitory effects of lycopene in cancer.
Authors:
Paola Palozza; Maria Colangelo; Rossella Simone; Assunta Catalano; Alma Boninsegna; Paola Lanza; Giovanni Monego; Franco O Ranelletti
Related Documents :
7658149 - Regulation of human apolipoprotein a-i expression in caco-2 and hepg2 cells by all-tran...
8155579 - Retinoic acid affects central nervous system development of xenopus by changing cell fate.
20847549 - Heparin-binding epidermal growth factor-like growth factor is a potent neurotrophic fac...
1671689 - Studies on the influence of the presence of an activated ras oncogene on the in vitro r...
7585519 - The h-ras oncogene interferes with retinoic acid signaling and metabolism in nih3t3 cells.
7586799 - In vitro invasiveness of du-145 human prostate carcinoma cells is modulated by egf rece...
6981699 - Nonspecific binding by macrophages: different modulation of adhesive properties of rat ...
2310929 - Estimation of growth fraction in situ in human bladder cancer with bromodeoxyuridine la...
23335999 - Assessment of tracer 99mtc(v)-dmsa uptake as a measure of tumor cell proliferation in v...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-10
Journal Detail:
Title:  Carcinogenesis     Volume:  31     ISSN:  1460-2180     ISO Abbreviation:  Carcinogenesis     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-08     Completed Date:  2010-11-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8008055     Medline TA:  Carcinogenesis     Country:  England    
Other Details:
Languages:  eng     Pagination:  1813-21     Citation Subset:  IM    
Affiliation:
Institute of General Pathology, Catholic University School of Medicine, L. Go F. Vito, 00168 Rome, Italy. p.palozza@rm.unicatt.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticarcinogenic Agents / pharmacology*
Apoptosis / drug effects
Carotenoids / pharmacology*
Cell Cycle / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Humans
Hydroxymethylglutaryl CoA Reductases / genetics
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
Male
Mevalonic Acid / metabolism*
NF-kappa B / metabolism
Neoplasms / drug therapy*,  metabolism,  pathology
Protein Transport / drug effects
Reactive Oxygen Species / metabolism
Signal Transduction / drug effects*
ras Proteins / physiology*
Chemical
Reg. No./Substance:
0/Anticarcinogenic Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/NF-kappa B; 0/Reactive Oxygen Species; 150-97-0/Mevalonic Acid; 36-88-4/Carotenoids; 502-65-8/lycopene; EC 1.1.1.-/Hydroxymethylglutaryl CoA Reductases; EC 3.6.5.2/ras Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Estimate of organ radiation absorbed doses in clinical CT using the radiation treatment planning sys...
Next Document:  A rare and undesirable complication of heparin-induced thrombocytopenia: acute massive pulmonary emb...